La Vita Compounding Pharmacy, LLC, San Diego, CA

Is La Vita Compounding Pharmacy, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does La Vita Compounding Pharmacy, LLC hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. The Colorado State Board of Pharmacy also lists nonresident license OSP 6029 for La Vita Compounding Pharmacy, San Diego, CA, status Expired, as of Nov 15, 2026.

Has La Vita Compounding Pharmacy, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Feb 28, 2019), 1 warning letter close-out (Sep 3, 2020), 1 state referral letter (Sep 3, 2020) and 1 FMD-145 letter (Sep 3, 2020) for La Vita Compounding Pharmacy, LLC. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists 3 actions: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended” dated Apr 29, 2023, case AC 6851 on license LSC 99842, “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years, subject to the terms and conditions in the decision” dated Apr 29, 2023, case AC 6851 on license PHY 48731 and “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years, subject to the terms and conditions in the decision” dated Apr 29, 2023, case AC 6851 on license PHY 58677. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Letter of Admonition” dated Aug 17, 2023, case 2023-4057 on nonresident license OSP 6029. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
La Vita Compounding Pharmacy, LLC
Location
San Diego, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
1
Latest action on that page
Sep 3, 2020
FDA Data Dashboard inspections
1 inspection: 1 VAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 9 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as La Vita Compounding Pharmacy, LLC, a 503A facility, with 5 dated actions.

Document
Sep 3, 2020State referral letterState Referral Letter Issued 09/03/2020Not linked by FDA
Sep 3, 2020Warning letter close-outWarning Letter Close Out Issued 09/03/2020Not linked by FDA
Sep 3, 2020FMD-145 letterFMD-145 Letter Issued 09/03/2020Not linked by FDA
Mar 11, 2020Form 483483 Issued 03/11/2020FDA copy (archived)
Feb 28, 2019Warning letterWarning Letter (02/28/2019)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists La Vita Compounding Pharmacy, LLC, San Diego, CA (FEI number 3009571102), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 11, 2020Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30095711021120486

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Jun 8, 2018 to Mar 11, 2020. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 4, 2020 to Mar 11, 2020: 4 observations

Firm on the cover
La Vita Compounding Pharmac y, LLC, 3978 Sorrento Valley Blvd Ste 300, San Diego, CA 92121-1436
FEI number
3009571102
Establishment type on the cover
Producer of Sterile and Non-Sterile Drugs
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, the firm purchases Methylcobalamin active ingredient from <Redacted B4> for use in the production of Methylcobalamin solution for injection. The firm has purchased and used <Redacted B4> lots of this active ingredient that lacks a description of grade. These ungraded active ingredient batches were used in the production of <Redacted B4> finished product batches:

Observation 2

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically, on 3/9/20 we observed Sterile Technician <Redacted B4> gowning. The sleeves of the cleanroom suit (non­sterile) came in contact with the floor of the ISO 8 ante room. The technician proceeded to enter the ISO 5 zone and produce Methylcobalamin batch 183570@8 BUD 9/5/20. Uncovered and non-sanitized sleeves were observed within the ISO 5 space.

Observation 3

The ISO 5 classified aseptic processing areas had particle generating and visibly dirty equipment or surface.

Specifically, the following equipment conditions were observed within the ISO 7 buffer room containing the ISO5 zone:

1. Rust-like discoloration below the seat of the chair at the ISO 5 LAFH. As well, white specks were observed on the seat of the chair on 3/4/20 while the room was in a cleaned status.

2. Rust-like discoloration of the garbage can was observed across all surfaces. The can is positioned within approximately 6 inches of the ISO 5 LAFH.

3. Extensive cracks are present on the <Redacted B4> of the <Redacted B4> the ISO 7 buffer room and the ISO 8 ante room respectively. More than four cracks pass through the entire depth of the <Redacted B4>. The <Redacted B4> is constructed of composite board with a plastic sheet coating glued together. All materials entering the ISO7 buffer room <Redacted B4> The <Redacted B4> the <Redacted B4> composite boards to <Redacted B4>

Observation 4

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.

Equipment within or in close proximity to the ISO 5 area could compromise the area in the ISO 5 area. Specifically, you keep a <Redacted B4> in the ISO 7 buffer room. During the cleanroom recertification activity on 1/25/19 third party cleanroom certification business <Redacted B4> identified an airborne viable environmental monitoring OOS (15 CFU) at location <Redacted B4> corresponding to the <Redacted B4> The PIC identified a preventative action of not permitting the operation of the <Redacted B4> during cleanroom recertification activities and a corrective action of cleaning and re-sampling the environment of the classified spaces. You have failed to investigate and eliminate the identified potential source of air contamination in the ISO 7 buffer room, background to the ISO 5 LAFH.

corrective action of cleaning and re-sampling the environment of the classified spaces. ...

Read the full 483 (PDF on fda.gov)

Inspection Jun 4, 2018 to Jun 8, 2018: 5 observations

Firm on the cover
La Vita Compounding Pharmacy, LLC 3978 Sorrento Valley Blvd STE 300, San Diego, CA 92121-1436
FEI number
3009571102
Establishment type on the cover
Prod ucer of N on- Ster ile and St e ril e Drug Pro ducts
FDA district office on the cover
Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Your firm produced drugs while construction was underway in an adjacent area without adequate controls to prevent contamination of the production environment and product.

Specifically,

Your firm produced non-sterile and sterile drugs while construction was underway in an adjacent area to <Redaced B4>. Controls and cleaning frequency may not be adequate to prevent contamination of the production environment and product. Dust was observed in the IS07 lab.

Entry to your non-sterile lab comes directly from a carpeted hallway and entry to the ISO controlled areas comes directly from the non-stelile lab directly adjacent to the new construction. There is construction containment in the hallway. An unused door in the non-sterile lab that leads directly to the new construction area was unsealed. There was no indication of carpet cleaning and no protective devices to prevent contamination from the carpet into the non-sterile lab

Observation 2

Unsealed, loose ceiling tiles were observed in your cleanroom.

Specifically,

The ISO classified aseptic processing areas had difficult to clean, particle generating and visibly dirty e quipment or surface. O n 6 /4/18 a nd 6/6/l8 I observed that your I S0-8 ante-room and ISO-7 Clean-ro om have ceiling tiles that are not sealed, have gaps between the tiles, and not impermeable to prevent du st or microbial contamination of the IS07 room and IS05 hood. The plastic cover of the light fixture dir ectly above the IS0-5 hood had two broken and missing corners. This could contribute to dust and ins anitary condition in the ISO controlled areas.

Observation 3

The segregated production areas surrounding the ISO 5 classified aseptic processing area contained dust-collecting overhangs without adequate and frequent cleaning.

Specifically,

On 6/4/18 and 6/6/l 8 I observed that the top of the ISO 5 hood, the frame and door of the <Redacted B4>., and the door and rear of the <Redacted B4> in the IS0 7 room had visible dust and dirt.

Observation 4

Specifically,

Your firm uses non-sterile gloves and non-sterile wipes for work in the ISO-8 ante-room, IS0-7 clean-room, and IS0-5 hood. On 6/4/18 and 6/6/18 I observed your sterile compounding technician explain and demonstrate to me her aseptic processing cleaning and production techniques. The technician used non-sterile gloves and non-sterile wipes for cleaning in the IS0 7 and IS0 8 rooms. The technician then changed and donned sterile gloves to clean inside the IS0 -5 hood using non-sterile wipes, water from a container that had been opened and dated 3/07 18, then sterile <Redacted B4> using non-sterile wipes. The technician left some of the used dirty non-sterile wipes in the IS0-5 hood. She continued to perform activities outside and inside of the IS0-5 hood. She used the same gloves that had been worn during cleaning for the aseptic production work without changing gloves and without frequent disinfecting.

Observation 5

Equipment was not disinfected prior to entering the aseptic processing areas.

Specifically,

a) On 6/4/1 8 and 6/6/18 I observed the sterile compounding technician explain and demonstrate to me

her technique for cleaning, preparing the IS0-7 clean-room and IS0-5 hood, and to perfonn sterile compounding. She explained more than once that the <Redacted B4> is not cleaned on the inside except <Redacted B4> (. Some of the equipment and glassware used in sterile processing were transferred from the ISO­8 ante-room, through the :<Redacted B4> , and then to the IS0-5 hood but the glassware was not sanitized on the outside prior to being placed in the IS0 5 hood. A 50ml graduate cylinder was taken from a cart in the IS07 room and placed in the IS05 hood lying down without being sanitized/wiped on the outside. Non-sterile wipes were used to clean the IS05 hood and left in the hood during aseptic processing.

b) Your firm uses non-medical grade plastic containers to store <Redacted B4> drug <Redacted B4> at room. temperature with up to a <Redacted B4> expiration. <Redacted B4> had an expiration of <Redacted B4>. <Redacted B4> expiration of <Redacted B4> . ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6029OSPLa Vita Compounding PharmacySan Diego, CAExpired

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.